Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab

This observational study is a large-scale, prospective, and multi-institutional observational study.Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet.

Inclusion Criteria:Adult aged 19 years to 75 years (on registration date)Patient scheduled to administer Fexuclue tablet based on the medical judgment of investigator.Patient who agreed to participate in this observation study and signed Informed Consent FormExclusion Criteria:A person who falls under the prohibition of administration according to the permission for Fexuclue TabletPatients with hypersensitivity to the components of Fexuclue tablet or Fexuclue tablet and a history thereofPatients undergoing Atazanavir, Nelfinavir or Lilpivirin-containing preparationsPregnant and lactating womenPatients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabortionA person who participates in another clinical trial and is administering (applying) clinical trial drugs or clinical trial medical devices;In addition to the above, a person who has determined that the researcher (the doctor in charge) is not suitable for participation in this observation study